# Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

> **NCT06858319** · PHASE3 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 220 (estimated)

## Conditions studied

- Kidney Diseases
- Kidney Diseases, Chronic
- Urological Diseases
- Glomerulonephritis
- Glomerular Disease
- Glomerulonephritis, IGA
- Glomerulopathy
- Immunoglobulin Disease

## Interventions

- **DRUG:** zigakibart

## Key facts

- **NCT ID:** NCT06858319
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-28
- **Primary completion:** 2031-06-25
- **Final completion:** 2031-06-25
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06858319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06858319, "Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT06858319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*